Skip to Main Content

Paper Details

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
JAMA Netw Open
33
2022
Metastatic Castration-Resistant Prostate Cancer, PSA, Prostate-specific antigen, TMB, TTNT, biomarker, cancer, mCRPC, men, metastatic castration-resistant prostate cancer, patient, patients, taxane, taxanes
Author NameAffiliation
Jeffrey S RossFoundation Medicine
Jeffrey S RossUpstate Medical University
Mia A LevyFoundation Medicine
Mia A LevyRush University Medical Center
Neeraj AgarwalHuntsman Cancer Institute, University of Utah
  • 1 - 5

Datasets

Release 1.2